Petros Pharmaceuticals (PTPI) Competitors $0.07 -0.02 (-19.65%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$0.07 0.00 (0.00%) As of 03/31/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. CDT, OGEN, PLRZ, GNPX, LIPO, UPXI, THAR, ARAV, PBM, and MTNBShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Conduit Pharmaceuticals (CDT), Oragenics (OGEN), Polyrizon (PLRZ), Genprex (GNPX), Lipella Pharmaceuticals (LIPO), Upexi (UPXI), Tharimmune (THAR), Aravive (ARAV), Psyence Biomedical (PBM), and Matinas Biopharma (MTNB). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Conduit Pharmaceuticals Oragenics Polyrizon Genprex Lipella Pharmaceuticals Upexi Tharimmune Aravive Psyence Biomedical Matinas Biopharma Conduit Pharmaceuticals (NASDAQ:CDT) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation. Which has more risk & volatility, CDT or PTPI? Conduit Pharmaceuticals has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Do analysts prefer CDT or PTPI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings & valuation, CDT or PTPI? Conduit Pharmaceuticals has higher earnings, but lower revenue than Petros Pharmaceuticals. Conduit Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConduit PharmaceuticalsN/AN/A-$540K-$39.33-0.02Petros Pharmaceuticals$4.02M0.19-$8.16M-$4.76-0.01 Do institutionals and insiders believe in CDT or PTPI? 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 30.9% of Conduit Pharmaceuticals shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer CDT or PTPI? Conduit Pharmaceuticals and Petros Pharmaceuticals both received 1 outperform votes by MarketBeat users. CompanyUnderperformOutperformConduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesPetros PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Does the media refer more to CDT or PTPI? In the previous week, Conduit Pharmaceuticals had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 4 mentions for Conduit Pharmaceuticals and 2 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.43 beat Conduit Pharmaceuticals' score of 0.39 indicating that Petros Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Conduit Pharmaceuticals Neutral Petros Pharmaceuticals Neutral Is CDT or PTPI more profitable? Conduit Pharmaceuticals' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Conduit PharmaceuticalsN/A N/A -328.67% Petros Pharmaceuticals N/A -78.22%-23.50% SummaryConduit Pharmaceuticals beats Petros Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Remove Ads Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$782,000.00$6.90B$5.64B$7.79BDividend YieldN/A2.81%5.34%4.04%P/E Ratio-0.017.4223.6318.68Price / Sales0.19207.00370.2189.79Price / CashN/A65.6738.1734.64Price / Book0.026.206.744.12Net Income-$8.16M$142.11M$3.20B$247.10M7 Day PerformanceN/A-7.27%-4.58%-3.13%1 Month PerformanceN/A-10.44%-0.24%-6.21%1 Year PerformanceN/A-12.86%8.08%-1.58% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.3877 of 5 stars$0.07-19.7%N/A-95.3%$782,000.00$4.02M-0.0120Upcoming EarningsGap DownCDTConduit Pharmaceuticals0.3065 of 5 stars$0.88+6.3%N/A-99.8%$3.20MN/A0.003Earnings ReportShort Interest ↑OGENOragenicsN/A$0.26flatN/A-85.4%$3.18M$40,000.00-0.045PLRZPolyrizonN/A$0.75+34.2%N/AN/A$3.14MN/A0.00N/AGap DownHigh Trading VolumeGNPXGenprex4.4018 of 5 stars$0.37+3.2%$10.00+2,608.6%-91.8%$3.14MN/A0.0020Upcoming EarningsPositive NewsLIPOLipella Pharmaceuticals3.3515 of 5 stars$2.56-1.2%$16.00+525.0%-54.2%$3.10M$483,533.00-0.604Earnings ReportNews CoverageUPXIUpexi0.8919 of 5 stars$2.31-0.9%N/A-82.0%$3.05M$18.63M0.00130THARTharimmune2.9288 of 5 stars$1.53+6.3%$17.00+1,011.1%-78.9%$2.96MN/A0.002Earnings ReportShort Interest ↓News CoverageGap DownHigh Trading VolumeARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading VolumePBMPsyence BiomedicalN/A$0.65+3.9%N/A-99.3%$2.94MN/A0.00N/AShort Interest ↓News CoverageMTNBMatinas BiopharmaN/A$0.58-3.8%N/AN/A$2.94M$1.10M-0.1230 Remove Ads Related Companies and Tools Related Companies Conduit Pharmaceuticals Competitors Oragenics Competitors Polyrizon Competitors Genprex Competitors Lipella Pharmaceuticals Competitors Upexi Competitors Tharimmune Competitors Aravive Competitors Psyence Biomedical Competitors Matinas Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTPI Stock Free PTPI Stock Alerts